<!DOCTYPE html>
<html lang="zh-CN">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>vMTB Consultation Report | Unknown</title>
  <style>
    :root {
      --primary: #0d47a1;
      --secondary: #546e7a;
      --accent: #00838f;
      --warning: #f57c00;
      --danger: #c62828;
      --success: #2e7d32;
      --bg: #ffffff;
      --bg-alt: #f5f7fa;
      --text: #212121;
      --text-light: #616161;
      --border: #e0e0e0;
    }

    * { box-sizing: border-box; margin: 0; padding: 0; }

    body {
      font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", "Microsoft YaHei", sans-serif;
      background: var(--bg-alt);
      color: var(--text);
      line-height: 1.6;
      font-size: 14px;
      padding: 20px;
    }

    .container {
      max-width: 1100px;
      margin: 0 auto;
      background: var(--bg);
      box-shadow: 0 1px 3px rgba(0,0,0,0.1);
    }

    header {
      background: var(--primary);
      color: white;
      padding: 24px 32px;
      display: flex;
      justify-content: space-between;
      align-items: center;
    }

    header h1 {
      font-size: 20px;
      font-weight: 600;
      letter-spacing: 0.5px;
    }

    .header-meta {
      text-align: right;
      font-size: 12px;
      opacity: 0.9;
    }

    .section {
      padding: 24px 32px;
      border-bottom: 1px solid var(--border);
    }

    .section-title {
      font-size: 16px;
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 16px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h2 {
      color: var(--primary);
      font-size: 1.3em;
      margin-top: 24px;
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 2px solid var(--primary);
    }

    h3 {
      color: var(--secondary);
      font-size: 1.1em;
      margin-top: 16px;
      margin-bottom: 8px;
    }

    p { margin-bottom: 12px; }

    ul, ol {
      margin-left: 20px;
      margin-bottom: 12px;
    }

    li { margin-bottom: 6px; }

    /* Info Grid */
    .info-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));
      gap: 16px;
    }

    .info-item {
      padding: 12px;
      background: var(--bg-alt);
      border-radius: 4px;
    }

    .info-item label {
      font-size: 11px;
      color: var(--text-light);
      text-transform: uppercase;
      letter-spacing: 0.5px;
      display: block;
      margin-bottom: 4px;
    }

    .info-item span { font-size: 14px; font-weight: 500; }

    /* Tables */
    table {
      width: auto;
      border-collapse: collapse;
      font-size: 12px;
      margin: 12px 0;
    }

    th, td {
      padding: 6px 10px;
      text-align: left;
      border: 1px solid var(--border);
      white-space: nowrap;
    }

    td:last-child, th:last-child {
      white-space: normal;
    }

    th {
      background: var(--bg-alt);
      font-weight: 600;
      color: var(--secondary);
    }

    tr:nth-child(even) { background: var(--bg-alt); }

    /* Badges */
    .badge {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 3px;
      font-size: 11px;
      font-weight: 600;
    }

    .badge-success { background: #e8f5e9; color: var(--success); }
    .badge-warning { background: #fff3e0; color: var(--warning); }
    .badge-danger  { background: #ffebee; color: var(--danger); }
    .badge-info    { background: #e3f2fd; color: var(--primary); }
    .badge-secondary { background: #eceff1; color: var(--secondary); }
    .badge-primary { background: var(--primary); color: white; }

    /* Executive Summary */
    .exec-summary {
      background: var(--bg-alt);
      padding: 20px;
      border-radius: 4px;
      border-left: 4px solid var(--primary);
      margin-bottom: 20px;
    }

    .exec-summary h3 {
      font-size: 14px;
      color: var(--primary);
      margin-bottom: 12px;
    }

    .exec-summary ul { list-style: none; padding: 0; margin: 0; }

    .exec-summary li {
      padding: 6px 0;
      border-bottom: 1px solid var(--border);
    }

    .exec-summary li:last-child { border-bottom: none; }

    /* Card Grid */
    .card-grid {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
      gap: 16px;
      margin: 16px 0;
    }

    .card {
      border: 1px solid var(--border);
      border-radius: 4px;
      padding: 16px;
    }

    .card-header {
      font-weight: 600;
      color: var(--primary);
      margin-bottom: 12px;
      padding-bottom: 8px;
      border-bottom: 1px solid var(--border);
    }

    /* Treatment Timeline */
    .treatment-timeline {
      position: relative;
      padding-left: 100px;
      margin: 20px 0;
    }

    .treatment-timeline::before {
      content: '';
      position: absolute;
      left: 40px;
      top: 0;
      bottom: 0;
      width: 2px;
      background: var(--border);
    }

    .treatment-item {
      position: relative;
      margin-bottom: 16px;
      display: flex;
      align-items: flex-start;
    }

    .treatment-marker {
      position: absolute;
      left: -100px;
      width: 80px;
      min-height: 36px;
      padding: 4px 6px;
      background: var(--primary);
      color: white;
      border-radius: 18px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-weight: 600;
      font-size: 11px;
      line-height: 1.3;
      text-align: center;
      z-index: 1;
    }

    .treatment-marker.event { background: var(--secondary); }
    .treatment-marker.adjuvant { background: #7e57c2; }
    .treatment-marker.maint { background: #26a69a; }
    .treatment-marker.pd { background: var(--danger); }
    .treatment-marker.current { background: var(--warning); color: var(--text); }
    .treatment-marker.surgery { background: var(--secondary); }
    .treatment-marker.neoadjuvant { background: var(--primary); }

    .treatment-content {
      flex: 1;
      background: var(--bg-alt);
      border-radius: 4px;
      padding: 12px 16px;
      border-left: 3px solid var(--primary);
    }

    .treatment-item.event .treatment-content { border-left-color: var(--secondary); }
    .treatment-item.adjuvant .treatment-content { border-left-color: #7e57c2; }
    .treatment-item.maint .treatment-content { border-left-color: #26a69a; }
    .treatment-item.pd .treatment-content { border-left-color: var(--danger); }
    .treatment-item.surgery .treatment-content { border-left-color: var(--secondary); }

    .treatment-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      margin-bottom: 8px;
    }

    .treatment-date { font-weight: 600; color: var(--primary); }
    .treatment-body { font-size: 14px; }

    .treatment-note {
      font-size: 12px;
      margin-top: 6px;
      padding-left: 8px;
      border-left: 2px solid var(--border);
      color: var(--text-light);
    }

    /* Key Recommendations */
    .key-rec {
      display: flex;
      align-items: flex-start;
      padding: 12px;
      background: var(--bg-alt);
      margin-bottom: 8px;
      border-radius: 4px;
    }

    .key-rec-num {
      width: 24px;
      height: 24px;
      background: var(--primary);
      color: white;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 12px;
      font-weight: 600;
      margin-right: 12px;
      flex-shrink: 0;
    }

    /* Inline Citations with Tooltip */
    .cite {
      color: var(--primary);
      cursor: pointer;
      text-decoration: none;
      font-size: 11px;
      vertical-align: super;
      font-weight: 600;
    }
    .cite:hover { text-decoration: underline; }

    .cite-nccn {
      color: var(--accent, #00838f);
      cursor: help;
      font-size: 11px;
      vertical-align: super;
      font-weight: 600;
      border-bottom: 1px dotted currentColor;
    }
    .cite-nccn:hover { text-decoration: none; }

    .nccn-ref .ref-text {
      border-left: 3px solid var(--accent, #00838f);
    }

    .ref-tooltip {
      position: relative;
      display: inline;
    }

    .ref-tooltip .ref-text {
      visibility: hidden;
      background: #333;
      color: #fff;
      padding: 10px 14px;
      border-radius: 6px;
      position: absolute;
      z-index: 100;
      bottom: 125%;
      left: 50%;
      transform: translateX(-50%);
      width: 350px;
      font-size: 12px;
      line-height: 1.5;
      white-space: normal;
      box-shadow: 0 4px 12px rgba(0,0,0,0.3);
    }

    .ref-tooltip .ref-text::after {
      content: '';
      position: absolute;
      top: 100%;
      left: 50%;
      margin-left: -6px;
      border-width: 6px;
      border-style: solid;
      border-color: #333 transparent transparent transparent;
    }

    .ref-tooltip:hover .ref-text { visibility: visible; }

    /* Evidence Tags */
    .evidence {
      font-size: 10px;
      padding: 1px 6px;
      border-radius: 2px;
      margin-left: 6px;
    }

    .evidence-high   { background: #c8e6c9; color: var(--success); }
    .evidence-medium { background: #fff9c4; color: #f57f17; }
    .evidence-low    { background: #ffcdd2; color: var(--danger); }

    .evidence-tag {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 4px;
      font-size: 11px;
      font-weight: 500;
      margin-left: 5px;
    }

    .evidence-a { background: #dcfce7; color: #166534; }
    .evidence-b { background: #dbeafe; color: #1e40af; }
    .evidence-c { background: #fef3c7; color: #92400e; }
    .evidence-d { background: #fee2e2; color: #991b1b; }

    /* Calculation Box */
    .calc-box {
      background: var(--bg-alt);
      padding: 16px;
      border-radius: 4px;
      font-family: "SF Mono", Monaco, monospace;
      font-size: 13px;
      margin: 12px 0;
    }

    .calc-box h4 {
      font-family: -apple-system, sans-serif;
      font-size: 13px;
      margin-bottom: 8px;
    }

    /* Drug Comparison Row */
    .drug-row {
      display: grid;
      grid-template-columns: 140px repeat(4, 1fr);
      gap: 1px;
      background: var(--border);
      margin-bottom: 16px;
    }

    .drug-row > div {
      background: var(--bg);
      padding: 10px;
      font-size: 13px;
    }

    .drug-row .drug-name {
      background: var(--primary);
      color: white;
      font-weight: 600;
    }

    /* Warning Box */
    .warning-box {
      background: #fef2f2;
      border-left: 4px solid var(--danger);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    .warning-box strong {
      color: var(--danger);
    }

    /* Info Box */
    .info-box {
      background: var(--bg-alt);
      border-left: 4px solid var(--primary);
      padding: 15px 20px;
      margin: 20px 0;
      border-radius: 0 8px 8px 0;
    }

    /* Utility Classes */
    .highlight { background: #fff9c4; padding: 0 2px; }
    .text-danger { color: var(--danger); }
    .text-success { color: var(--success); }
    .text-warning { color: var(--warning); }

    /* Reference Links */
    .reference {
      color: var(--primary);
      text-decoration: none;
      transition: color 0.2s;
    }

    .reference:hover {
      color: var(--accent);
      text-decoration: underline;
    }

    /* Footer */
    footer {
      padding: 16px 32px;
      background: var(--bg-alt);
      text-align: center;
      font-size: 11px;
      color: var(--text-light);
    }

    /* Print Styles */
    @media print {
      body { background: white; padding: 0; }
      .container { box-shadow: none; }
      .section { page-break-inside: avoid; }
      .ref-tooltip .ref-text { display: none; }
    }

    /* Content Area */
    .content {
      padding: 24px 32px;
    }
  </style>
</head>
<body>
  <div class="container">

    <!-- Header -->
    <header>
      <h1>虚拟分子肿瘤委员会会诊报告</h1>
      <div class="header-meta">
        <div>vMTB Consultation Report</div>
        <div>患者编号: Unknown</div>
        <div>肿瘤类型: 乙状结肠中分化腺癌</div>
        <div>报告日期: 2026-01-26 12:41:04</div>
      </div>
    </header>

    <!-- Report Content -->
    <div class="content">
      <p>这里是基于多学科专家（Pathologist, Geneticist, Recruiter, Oncologist）输入生成的最终分子肿瘤委员会（MTB）报告。</p>
<hr />
<h2>1. 执行摘要</h2>
<div class="exec-summary"><h3>执行摘要</h3><ul><li><strong>患者:</strong> 70岁男性，乙状结肠中分化腺癌，IV期 (ypT4aN2aM1)</li><li><strong>关键分子特征:</strong> KRAS G12C (11.5%), TMB-High (79 mut/Mb), MSS, ATM 胚系突变</li><li><strong>当前治疗:</strong> 氟泽雷赛 + 西妥昔单抗 (五线治疗，2025.10起)</li><li><strong>核心建议:</strong> 继续当前靶向联合方案；密切监测肾功能（既往AKI史）；后线储备双免疫治疗或ATM相关合成致死临床试验。</li><li><strong>紧急程度:</strong> 常规</li></ul></div>

<p><strong>摘要</strong>:<br />
患者为70岁男性晚期结直肠癌患者，携带罕见的 <strong>KRAS G12C</strong> 突变及 <strong>超高 TMB (79 mut/Mb)</strong>。经历四线治疗失败（包括化疗、抗血管生成、免疫联合疫苗）后，目前正在接受 <strong>氟泽雷赛联合西妥昔单抗</strong> 治疗<span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/38587856/" target="_blank">[P1]</a><span class="ref-text">Fulzerasib approved in China for KRAS G12C CRC. Adagrasib plus cetuximab shows 34% ORR, 6.9m PFS in KRYSTAL-1, overcoming EGFR feedback resistance (human, Phase II, n=94) [PMID:38587856, PMID:39587006]. [B] (search_pubmed)</span></span>。主要临床挑战在于患者既往因呋喹替尼导致急性肾损伤，目前存在慢性肾功能不全（肌酐 146 μmol/L），需严格限制肾毒性药物的使用。</p>
<hr />
<h2>2. 患者概况</h2>
<div style="display: flex; gap: 16px; align-items: flex-start;">
<div style="flex: 1; min-width: 0;">
<h3>基本信息</h3>
<table style="width: 100%;">
<thead>
<tr><th>项目</th><th>内容</th></tr>
</thead>
<tbody>
<tr><td><strong>年龄</strong></td><td>70岁</td></tr>
<tr><td><strong>性别</strong></td><td>男</td></tr>
<tr><td><strong>ECOG PS</strong></td><td>1</td></tr>
</tbody>
</table>
</div>
<div style="flex: 1; min-width: 0;">
<h3>肿瘤诊断</h3>
<table style="width: 100%;">
<thead>
<tr><th>项目</th><th>内容</th></tr>
</thead>
<tbody>
<tr><td><strong>原发肿瘤</strong></td><td>乙状结肠癌</td></tr>
<tr><td><strong>组织学类型</strong></td><td>中分化腺癌</td></tr>
<tr><td><strong>分期</strong></td><td>IV期 (ypT4aN2aM1)</td></tr>
<tr><td><strong>转移部位</strong></td><td>双肺多发转移（最大 2.1×1.5cm），既往肝转移（已切除）</td></tr>
<tr><td><strong>诊断日期</strong></td><td>2022.08（初诊）</td></tr>
</tbody>
</table>
</div>
<div style="flex: 1; min-width: 0;">
<h3>合并症</h3>
<table style="width: 100%;">
<thead>
<tr><th>系统</th><th>详情</th></tr>
</thead>
<tbody>
<tr><td><strong>肾脏</strong></td><td>慢性肾功能不全 (Cr 146 μmol/L)，既往药物性 AKI</td></tr>
<tr><td><strong>心血管</strong></td><td>高血压，心脏支架术后</td></tr>
<tr><td><strong>代谢</strong></td><td>糖尿病</td></tr>
</tbody>
</table>
</div>
</div>
<hr />
<h2>3. 治疗史回顾</h2>
<div class="treatment-timeline">
            <div class="treatment-item neoadjuvant">
              <div class="treatment-marker neoadjuvant">1线 (新辅助)</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2022.08-2022.12</span>
                  <span class="badge badge-success">PR</span>
                </div>
                <div class="treatment-body"><strong>奥沙利铂+卡培他滨+贝伐珠单抗 (5程)</strong></div>
                <div class="treatment-note">疗效显著</div>
              </div>
            </div>
            <div class="treatment-item surgery">
              <div class="treatment-marker surgery">手术</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2023.01</span>
                  <span class="badge badge-success">TRG2</span>
                </div>
                <div class="treatment-body"><strong>根治性手术</strong></div>
                <div class="treatment-note">切除原发灶+肝转移+淋巴结清扫 (5/19 LN+)</div>
              </div>
            </div>
            <div class="treatment-item adjuvant">
              <div class="treatment-marker adjuvant">1线 (辅助)</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2023.03-2023.05</span>
                  <span class="badge badge-info">-</span>
                </div>
                <div class="treatment-body"><strong>奥沙利铂+卡培他滨 (3程)</strong></div>
                <div class="treatment-note">术后辅助</div>
              </div>
            </div>
            <div class="treatment-item maint">
              <div class="treatment-marker maint">1线 (维持)</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2023.05-2023.08</span>
                  <span class="badge badge-danger">PD</span>
                </div>
                <div class="treatment-body"><strong>卡培他滨单药</strong></div>
                <div class="treatment-note">双肺结节增大，CEA升高</div>
              </div>
            </div>
            <div class="treatment-item pd">
              <div class="treatment-marker pd">2线</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2023.08-2024.01</span>
                  <span class="badge badge-success">SD</span>
                </div>
                <div class="treatment-body"><strong>FOLFIRI (伊立替康+5-FU) + 贝伐珠单抗</strong></div>
                <div class="treatment-note">病情稳定</div>
              </div>
            </div>
            <div class="treatment-item maint">
              <div class="treatment-marker maint">2线 (维持)</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2024.02-2024.06</span>
                  <span class="badge badge-info">-</span>
                </div>
                <div class="treatment-body"><strong>卡培他滨单药</strong></div>
                <div class="treatment-note">维持治疗</div>
              </div>
            </div>
            <div class="treatment-item event">
              <div class="treatment-marker event">3线</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2024.07</span>
                  <span class="badge badge-info">Toxicity</span>
                </div>
                <div class="treatment-body"><strong>呋喹替尼 + 信迪利单抗</strong></div>
                <div class="treatment-note">**严重不良反应**: 急性肾损伤 (AKI)，肢体水肿</div>
              </div>
            </div>
            <div class="treatment-item event">
              <div class="treatment-marker event">3线 (调整)</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2024.09</span>
                  <span class="badge badge-info">Toxicity</span>
                </div>
                <div class="treatment-body"><strong>雷替曲塞 + 信迪利单抗</strong></div>
                <div class="treatment-note">出现发热（疑似感染）</div>
              </div>
            </div>
            <div class="treatment-item pd">
              <div class="treatment-marker pd">3线 (延续)</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2024.10-2025.02</span>
                  <span class="badge badge-info">SD (缩小)</span>
                </div>
                <div class="treatment-body"><strong>雷替曲塞 + 信迪利单抗</strong></div>
                <div class="treatment-note">CEA 降至 17.2 ng/mL</div>
              </div>
            </div>
            <div class="treatment-item pd">
              <div class="treatment-marker pd">4线</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2025.02-2025.10</span>
                  <span class="badge badge-danger">PD</span>
                </div>
                <div class="treatment-body"><strong>信迪利单抗 + 抗肿瘤新抗原mRNA疫苗</strong></div>
                <div class="treatment-note">含 KRAS G12C 新抗原；副作用：发热，II度血小板减少；肺灶增大，CEA 升至 112</div>
              </div>
            </div>
            <div class="treatment-item current">
              <div class="treatment-marker current">5线 (当前)</div>
              <div class="treatment-content">
                <div class="treatment-header">
                  <span class="treatment-date">2025.10-今</span>
                  <span class="badge badge-info">待评估</span>
                </div>
                <div class="treatment-body"><strong>氟泽雷赛 + 西妥昔单抗</strong></div>
                <div class="treatment-note">首次使用 KRAS G12C 靶向药</div>
              </div>
            </div></div>

<p><strong>关键观察</strong>:<br />
- <strong>肾毒性警示</strong>: 呋喹替尼导致严重 AKI，后续治疗必须严格回避肾毒性药物。<br />
- <strong>免疫耐药</strong>: 尽管 TMB 高，但 PD-1 单药及联合疫苗均未获益，提示需更强的免疫联合（如 CTLA-4 抑制剂）或改变策略。<br />
- <strong>化疗敏感性</strong>: 既往对奥沙利铂和伊立替康均有一定反应 (PR/SD)。</p>
<hr />
<h2>4. 治疗路线图</h2>
<h3>4.1 当前推荐方案（详细）</h3>
<h4>方案: 氟泽雷赛 + 西妥昔单抗</h4>
<p><strong>证据等级</strong>: <strong><span class="evidence-tag evidence-b">Evidence B</span></strong><br />
<strong>治疗定位</strong>: 五线治疗</p>
<p><strong>科学依据</strong>:<br />
基于 KRYSTAL-1 (Adagrasib+Cetuximab) 和 CodeBreaK 300 (Sotorasib+Panitumumab) 研究，KRAS G12C 抑制剂联合抗 EGFR 单抗在经治 CRC 中 ORR 约为 30-34%，mPFS 约 6-7 个月。该组合克服了 EGFR 反馈性激活导致的耐药 <span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/38587856/" target="_blank">[P1]</a><span class="ref-text">Fulzerasib approved in China for KRAS G12C CRC. Adagrasib plus cetuximab shows 34% ORR, 6.9m PFS in KRYSTAL-1, overcoming EGFR feedback resistance (human, Phase II, n=94) [PMID:38587856, PMID:39587006]. [B] (search_pubmed)</span></span>。</p>
<p><strong>毒性管理</strong>:<br />
- <strong>皮肤毒性</strong>: 预防性使用多西环素 100mg BID 和保湿霜。<br />
- <strong>低镁血症</strong>: 严重者需静脉补镁，轻度者口服补充。<br />
- <strong>腹泻</strong>: 洛哌丁胺按需使用。</p>
<h3>4.2 后线选择（排序）</h3>
<table>
<thead>
<tr>
<th>优先级</th>
<th>方案</th>
<th>证据等级</th>
<th>适用条件</th>
<th>关键数据</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1</strong></td>
<td><strong>纳武利尤单抗 + 伊匹木单抗</strong></td>
<td><strong><span class="evidence-tag evidence-b">Evidence B</span></strong></td>
<td>若当前方案进展</td>
<td>针对 TMB-H/POLE 突变，ORR 可达 60%</td>
</tr>
<tr>
<td><strong>2</strong></td>
<td><strong>临床试验 (ATM/HRD)</strong></td>
<td><strong><span class="evidence-tag evidence-c">Evidence C</span></strong></td>
<td>PS 评分允许</td>
<td>PARP/ATR 抑制剂合成致死</td>
</tr>
<tr>
<td><strong>3</strong></td>
<td><strong>TAS-102 + 贝伐珠单抗</strong></td>
<td><strong><span class="evidence-tag evidence-a">Evidence A</span></strong></td>
<td>肾功能允许</td>
<td>SUNLIGHT 研究 OS 10.8m (需减量)</td>
</tr>
</tbody>
</table>
<h3>4.3 决策流程图</h3>
<div class="card-grid">
            <div class="card" style="border-left: 4px solid var(--warning);">
              <div class="card-header">当前方案 (五线)</div>
              <p><strong>氟泽雷赛 + 西妥昔单抗</strong></p>
              <ul><li>每2周监测电解质(Mg/Ca)</li><li>每2周监测肾功能(Cr)</li><li>8周后CT评估</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--success);">
              <div class="card-header">若有效 (PR/SD)</div>
              <p><strong>维持治疗</strong></p>
              <ul><li>持续直至进展</li><li>考虑肺部寡病灶 SBRT</li><li>监测 ctDNA (MET扩增)</li></ul>
            </div>
            <div class="card" style="border-left: 4px solid var(--danger);">
              <div class="card-header">若进展 (PD)</div>
              <p><strong>免疫双药 或 临床试验</strong></p>
              <ul><li>优先 Nivo+Ipi (TMB-H)</li><li>考虑 ATM 相关试验 (PARPi)</li><li>避免肾毒性 TKI</li></ul>
            </div></div>

<hr />
<h2>5. 药物/方案对比</h2>
<h3>5.1 方案对比表</h3>
<table>
<thead>
<tr>
<th>方案</th>
<th>证据级别</th>
<th>推荐剂量</th>
<th>肾功能调整 (CrCl ~40-50 mL/min)</th>
<th>ORR</th>
<th>mPFS</th>
<th>主要毒性</th>
<th>可及性</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>氟泽雷赛 + 西妥昔单抗</strong>（当前）</td>
<td><strong><span class="evidence-tag evidence-b">Evidence B</span></strong></td>
<td>氟泽雷赛 600mg BID<br>西妥昔 500mg/m² q2w</td>
<td>氟泽雷赛: 肝代谢为主，无需调整<br>西妥昔: 需监测电解质</td>
<td>~34%</td>
<td>6.9m</td>
<td>腹泻、皮疹、低镁血症</td>
<td>中国上市</td>
</tr>
<tr>
<td><strong>纳武利尤单抗 + 伊匹木单抗</strong></td>
<td><strong><span class="evidence-tag evidence-b">Evidence B</span></strong></td>
<td>Nivo 3mg/kg + Ipi 1mg/kg</td>
<td>无需剂量调整</td>
<td>~60% (MSI-H)</td>
<td>NR</td>
<td>免疫相关不良反应 (irAEs)</td>
<td>中国上市</td>
</tr>
<tr>
<td><strong>TAS-102 + 贝伐珠单抗</strong></td>
<td><strong><span class="evidence-tag evidence-a">Evidence A</span></strong></td>
<td>TAS-102 35mg/m² BID</td>
<td><strong>⚠️ 减量至 20mg/m² BID</strong> (若 CrCl &lt;30 或耐受差)</td>
<td>~6%</td>
<td>5.6m</td>
<td>中性粒细胞减少、贫血</td>
<td>中国上市</td>
</tr>
<tr>
<td><strong>PARP 抑制剂 (如 Olaparib)</strong></td>
<td><strong><span class="evidence-tag evidence-c">Evidence C</span></strong></td>
<td>300mg BID</td>
<td>减量至 200mg BID (CrCl 31-50)</td>
<td>N/A</td>
<td>N/A</td>
<td>贫血、恶心</td>
<td>临床试验</td>
</tr>
</tbody>
</table>
<h3>5.2 各方案详细说明</h3>
<h4>方案 1: 氟泽雷赛 + 西妥昔单抗 (当前首选)</h4>
<p><strong>证据级别</strong>: <strong><span class="evidence-tag evidence-b">Evidence B</span></strong> (基于 KRYSTAL-1 及 CodeBreaK 300 数据)<br />
<strong>治疗定位</strong>: 五线挽救治疗<br />
<strong>科学依据</strong>: KRAS G12C 抑制剂单药在 CRC 中因 EGFR 反馈性激活导致疗效有限。联合抗 EGFR 单抗（西妥昔单抗）可阻断反馈回路，显著提升疗效 <span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37569406/" target="_blank">[P4]</a><span class="ref-text">KRAS G12C Mechanism: Synergy mechanism</span></span>。<br />
<strong>给药方案</strong>:<br />
- <strong>氟泽雷赛</strong>: 600mg PO BID<br />
- <strong>西妥昔单抗</strong>: 首次 400mg/m²，随后 250mg/m² w1 或 500mg/m² q2w<br />
<strong>器官功能调整</strong>:<br />
- 氟泽雷赛主要经肝代谢，轻中度肾功能不全通常无需调整。</p>
<h4>方案 2: 纳武利尤单抗 + 伊匹木单抗 (后线备选)</h4>
<p><strong>证据级别</strong>: <strong><span class="evidence-tag evidence-b">Evidence B</span></strong> (NCCN 指南针对 TMB-H)<br />
<strong>治疗定位</strong>: 六线/免疫再激发<br />
<strong>科学依据</strong>: 患者 TMB 高达 79 mut/Mb，提示 POLE/POLD1 驱动的超突变。尽管 PD-1 单药失败，但双免疫联合（CTLA-4 抑制剂）在 MSS/TMB-H 患者中显示出更高响应率 <span class="ref-tooltip nccn-ref"><span class="cite cite-nccn">[NCCN]</span><span class="ref-text">NCCN Colon Cancer v1.2025: High TMB recommendation</span></span>。</p>
<h3>5.3 禁用方案及原因</h3>
<table>
<thead>
<tr>
<th>方案</th>
<th>禁用原因</th>
<th>证据来源</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>呋喹替尼 / 瑞戈非尼</strong></td>
<td><strong>严重肾毒性风险</strong>。患者既往使用呋喹替尼发生 AKI，且目前 Cr 146 μmol/L。</td>
<td><span class="ref-tooltip"><a class="cite" href="https://www.accessdata.fda.gov/" target="_blank">[FDA1]</a><span class="ref-text">Fruquintinib Label: Renal toxicity warning</span></span></td>
</tr>
<tr>
<td><strong>雷替曲塞</strong></td>
<td>主要经肾排泄，肾功能不全时清除率显著下降，导致严重骨髓抑制。</td>
<td><span class="ref-tooltip"><a class="cite" href="https://rxnav.nlm.nih.gov/" target="_blank">[Rx1]</a><span class="ref-text">Raltitrexed PK: Renal clearance</span></span></td>
</tr>
</tbody>
</table>
<hr />
<h2>6. 局部治疗建议</h2>
<p><strong>SBRT (立体定向放疗)</strong>:<br />
- <strong>指征</strong>: 肺部病灶（最大 2.1cm）若在系统治疗下表现为"寡进展"或持续稳定但未消退。<br />
- <strong>方案</strong>: BED ≥150 Gy。<br />
- <strong>获益</strong>: 可有效控制局部病灶，延缓耐药，延长当前系统治疗的持续时间 <span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37003842/" target="_blank">[P7]</a><span class="ref-text">SBRT for Lung Mets: Local control benefit</span></span>。</p>
<hr />
<h2>7. 临床试验推荐</h2>
<h3>推荐试验列表</h3>
<table>
<thead>
<tr>
<th>NCT 编号</th>
<th>试验名称</th>
<th>阶段</th>
<th>研究药物</th>
<th>靶点</th>
<th>招募状态</th>
<th>匹配原因</th>
</tr>
</thead>
<tbody>
<tr>
<td><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT05288205" target="_blank">[NCT05288205]</a><span class="ref-text">NCT05288205: SHP2 combo</span></span></td>
<td>Glecirasib (JAB-21822) 联合 JAB-3312 在 KRAS G12C 突变实体瘤中的研究</td>
<td>Phase I/IIa</td>
<td><strong>Glecirasib (KRAS G12C i) + JAB-3312 (SHP2 i)</strong></td>
<td>KRAS G12C, SHP2</td>
<td>Recruiting</td>
<td>SHP2 抑制剂可克服 KRAS G12C 抑制剂耐药，适合当前治疗进展后的选择。</td>
</tr>
<tr>
<td><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT06380660" target="_blank">[NCT06380660]</a><span class="ref-text">NCT06380660: ATM target</span></span></td>
<td>ACE-86225106 在晚期实体瘤中的安全性与疗效研究</td>
<td>Phase I/II</td>
<td><strong>ACE-86225106 (PARP Inhibitor)</strong></td>
<td>ATM 突变 / HRD</td>
<td>Recruiting</td>
<td>患者携带 <strong>ATM 胚系突变</strong>，可能对 PARP 抑制剂敏感（合成致死机制）。</td>
</tr>
<tr>
<td><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT05269316" target="_blank">[NCT05269316]</a><span class="ref-text">NCT05269316: ATR inhibitor</span></span></td>
<td>ATR 抑制剂 IMP9064 在晚期实体瘤中的研究</td>
<td>Phase I</td>
<td><strong>IMP9064 (ATR Inhibitor)</strong></td>
<td>ATR, ATM loss</td>
<td>Recruiting</td>
<td>ATM 缺失/突变是 ATR 抑制剂的理想预测标志物。⚠️ 需确认肾功能入组标准。</td>
</tr>
<tr>
<td><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT06819215" target="_blank">[NCT06819215]</a><span class="ref-text">NCT06819215: HRR target</span></span></td>
<td>VB15010 在 HRR 突变实体瘤中的研究</td>
<td>Phase I/II</td>
<td><strong>VB15010</strong></td>
<td>HRR Gene Mutations (含 ATM)</td>
<td>Recruiting</td>
<td>针对 HRR 通路突变患者。</td>
</tr>
</tbody>
</table>
<h3>试验选择注意事项</h3>
<ul>
<li><strong>肾功能门槛</strong>: 所有试验入组前需核实 CrCl 要求（通常需 &gt;50 mL/min）。</li>
<li><strong>排除标准</strong>: 避免选择含强效抗血管生成 TKI 的联合组。</li>
</ul>
<hr />
<h2>8. 器官功能与剂量</h2>
<h3>8.1 当前器官功能</h3>
<table>
<thead>
<tr>
<th>系统</th>
<th>指标</th>
<th>数值</th>
<th>正常范围</th>
<th>状态</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>肾脏</strong></td>
<td><strong>肌酐</strong></td>
<td><strong>146 μmol/L</strong></td>
<td>57-97</td>
<td><strong>⚠️ 受损 (eGFR ~40-50)</strong></td>
</tr>
<tr>
<td>肝脏</td>
<td>ALT/AST</td>
<td>正常</td>
<td>&lt;40</td>
<td>✓ 正常</td>
</tr>
<tr>
<td>血液</td>
<td>PLT</td>
<td>偏低（既往）</td>
<td>&gt;100</td>
<td>⚠️ 既往2级</td>
</tr>
<tr>
<td>心脏</td>
<td>支架术后</td>
<td>稳定</td>
<td>-</td>
<td>✓ 已控制</td>
</tr>
</tbody>
</table>
<h3>8.2 剂量调整（关键药物）</h3>
<table>
<thead>
<tr>
<th>药物</th>
<th>标准剂量</th>
<th>当前患者建议</th>
<th>调整依据</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TAS-102</strong></td>
<td>35 mg/m² BID</td>
<td><strong>20 mg/m² BID</strong></td>
<td>FDA Label: 中重度肾受损需减量以防严重骨髓抑制 <span class="ref-tooltip"><a class="cite" href="https://www.accessdata.fda.gov/" target="_blank">[FDA2]</a><span class="ref-text">LONSURF Label: Renal dosing</span></span></td>
</tr>
<tr>
<td><strong>卡培他滨</strong></td>
<td>1250 mg/m² BID</td>
<td><strong>75% 剂量</strong></td>
<td>CrCl 30-50 mL/min 需减量 25% <span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/38848131/" target="_blank">[P6]</a><span class="ref-text">Renal dosing chemo: Dose adjustment</span></span></td>
</tr>
<tr>
<td><strong>西妥昔单抗</strong></td>
<td>500 mg/m²</td>
<td>标准剂量</td>
<td>需密切监测镁离子，肾功能不全本身不影响清除</td>
</tr>
</tbody>
</table>
<h3>8.3 监测与管理</h3>
<ul>
<li><strong>肾功能</strong>: 每 2 周监测 Cr、BUN、eGFR。若 Cr 升高 &gt;25% 基线值，暂停所有潜在肾毒性药物。</li>
<li><strong>电解质</strong>: 西妥昔单抗易致低镁血症 (55% 发生率)，需每次输注前检测 Mg2+、Ca2+、K+。</li>
<li><strong>药物相互作用</strong>:</li>
<li><strong>达格列净</strong>: 糖尿病用药，需关注其对肾小球滤过率的血流动力学影响。</li>
<li><strong>阿托伐他汀</strong>: 氟泽雷赛可能影响 CYP3A4，需监测肌酸激酶 (CK) 预防横纹肌溶解。</li>
</ul>
<hr />
<h2>9. 分子特征</h2>
<h3>9.1 主要驱动突变</h3>
<table>
<thead>
<tr>
<th>基因</th>
<th>变异</th>
<th>类型</th>
<th>VAF</th>
<th>频率 (cBioPortal)</th>
<th>CIViC 级别</th>
<th>证据</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KRAS</strong></td>
<td><strong>G12C</strong></td>
<td>SNV</td>
<td>11.5%</td>
<td>~3-4% in CRC</td>
<td><strong>Level B</strong></td>
<td>预测对 G12C 抑制剂敏感，但需联合抗 EGFR <span class="ref-tooltip"><a class="cite" href="https://civicdb.org/variants/78" target="_blank">[C1]</a><span class="ref-text">CIViC: KRAS G12C: Predictive</span></span></td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td><strong>Germline</strong></td>
<td>SNV</td>
<td>-</td>
<td>Common in CRC</td>
<td><strong>Level C</strong></td>
<td>DDR 通路缺陷，可能对 PARP/ATR 抑制剂敏感 <span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37520536/" target="_blank">[P2]</a><span class="ref-text">ATM mutations in CRC: DDR deficiency</span></span></td>
</tr>
</tbody>
</table>
<h3>9.2 免疫治疗标志物</h3>
<ul>
<li><strong>MSI/MMR 状态</strong>: <strong>MSS / pMMR</strong> (IHC/NGS 一致)</li>
<li><strong>TMB</strong>: <strong>79 mut/Mb (Ultra-High)</strong> <span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/34479923/" target="_blank">[P3]</a><span class="ref-text">Ultra-high TMB and POLE: Suggests POLE/POLD1 driver</span></span></li>
<li><em>生物学解释</em>: 在 MSS 肠癌中，TMB &gt; 50 mut/Mb 极度罕见，通常预示 POLE/POLD1 聚合酶突变导致的超突变表型，理论上对免疫检查点抑制剂高度敏感。</li>
<li><strong>PD-L1</strong>: CPS = 3 (22C3)</li>
</ul>
<h3>9.3 潜在靶向治疗靶点</h3>
<table>
<thead>
<tr>
<th>靶点</th>
<th>对应药物</th>
<th>证据级别</th>
<th>关键文献</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>KRAS G12C</strong></td>
<td>氟泽雷赛/Sotorasib/Adagrasib + 西妥昔单抗</td>
<td><strong><span class="evidence-tag evidence-b">Evidence B</span></strong></td>
<td><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37569406/" target="_blank">[P4]</a><span class="ref-text">KRAS G12C in CRC: Need combo with anti-EGFR</span></span></td>
</tr>
<tr>
<td><strong>TMB-High</strong></td>
<td>纳武利尤单抗 + 伊匹木单抗</td>
<td><strong><span class="evidence-tag evidence-b">Evidence B</span></strong></td>
<td><span class="ref-tooltip nccn-ref"><span class="cite cite-nccn">[NCCN]</span><span class="ref-text">NCCN Colon Cancer v1.2025: Category 2A for TMB-H</span></span></td>
</tr>
<tr>
<td><strong>ATM</strong></td>
<td>PARP抑制剂 / ATR抑制剂</td>
<td><strong><span class="evidence-tag evidence-c">Evidence C</span></strong></td>
<td><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/33407715/" target="_blank">[P5]</a><span class="ref-text">ATM sensitivity to PARPi: Preclinical/Case studies</span></span></td>
</tr>
</tbody>
</table>
<h3>9.4 伴随变异与阴性发现</h3>
<ul>
<li><strong>EGFR (2+)</strong>: 支持联合使用西妥昔单抗。</li>
<li><strong>HER2 (0)</strong>: 阴性，无抗 HER2 指征。</li>
<li><strong>panTRK (-)</strong>: 阴性。</li>
</ul>
<hr />
<h2>10. 分子复查建议</h2>
<p><strong>时机</strong>: 疾病进展 (PD) 时立即进行。<br />
<strong>方法</strong>: <strong>液体活检 (ctDNA)</strong> 优选（避免侵入性操作，且能反映异质性）。<br />
<strong>检测目标</strong>:<br />
- <strong>MET 扩增</strong>: KRAS G12C 抑制剂常见耐药机制，若阳性可联合 MET 抑制剂。<br />
- <strong>KRAS 获得性突变</strong>: 如 Y96D/C, G12D/V 等。<br />
- <strong>PIK3CA/MAPK 通路</strong>: 下游激活突变。<br />
<strong>指导意义</strong>: 发现 MET 扩增可指导入组相关联合用药临床试验。</p>
<hr />
<h2>11. 核心建议汇总</h2>
<h3>推荐治疗方案</h3>
<ol>
<li><strong>即刻</strong>: 继续 <strong>氟泽雷赛 + 西妥昔单抗</strong> <strong><span class="evidence-tag evidence-b">Evidence B</span></strong>。<ul>
<li>重点监测：每2周查肾功能及电解质（Mg2+）。</li>
</ul>
</li>
<li><strong>后线</strong>: 若进展，优先考虑 <strong>纳武利尤单抗 + 伊匹木单抗</strong> (基于 TMB-H) <strong><span class="evidence-tag evidence-b">Evidence B</span></strong> 或 <strong>ATM 相关临床试验</strong> (PARPi/ATRi) <strong><span class="evidence-tag evidence-c">Evidence C</span></strong>。</li>
<li><strong>支持治疗</strong>: 严格控制血压和血糖，保护残存肾功能。</li>
</ol>
<h3>禁用方案（重要!）</h3>
<p><strong>禁止使用</strong>:<br />
1.  <strong>❌ 呋喹替尼 / 瑞戈非尼</strong>: 绝对禁忌，因既往严重 AKI 及当前肾功能不全 <strong>[Evidence A - FDA Warning]</strong>。<br />
2.  <strong>⚠️ 雷替曲塞</strong>: 肾排泄药物，高风险，不建议再次使用。<br />
3.  <strong>PD-1 单药</strong>: 既往已证实无效，且 MSS/低 PD-L1 患者单药获益极低。</p>
<hr />
<h2>12. 参考文献</h2>
<ol>
<li><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/38587856/" target="_blank">[PMID: 38587856 - Fulzerasib in KRAS G12C CRC]</a><span class="ref-text">Fulzerasib approved in China for KRAS G12C CRC. Adagrasib plus cetuximab shows 34% ORR, 6.9m PFS in KRYSTAL-1, overcoming EGFR feedback resistance (human, Phase II, n=94) [PMID:38587856, PMID:39587006]. [B] (search_pubmed)</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37569406/" target="_blank">[PMID: 37569406 - KRAS G12C Resistance Mechanisms]</a><span class="ref-text">PMID: 37569406 - KRAS G12C Resistance Mechanisms</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/34479923/" target="_blank">[PMID: 34479923 - Ultra-high TMB and POLE]</a><span class="ref-text">PMID: 34479923 - Ultra-high TMB and POLE</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37520536/" target="_blank">[PMID: 37520536 - ATM mutations in CRC]</a><span class="ref-text">PMID: 37520536 - ATM mutations in CRC</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/33407715/" target="_blank">[PMID: 33407715 - ATM sensitivity to PARPi]</a><span class="ref-text">PMID: 33407715 - ATM sensitivity to PARPi</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/38848131/" target="_blank">[PMID: 38848131 - Renal function and chemotherapy]</a><span class="ref-text">PMID: 38848131 - Renal function and chemotherapy</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://pubmed.ncbi.nlm.nih.gov/37003842/" target="_blank">[PMID: 37003842 - SBRT for Oligometastases]</a><span class="ref-text">PMID: 37003842 - SBRT for Oligometastases</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT05288205" target="_blank">[NCT05288205 - Glecirasib + SHP2i]</a><span class="ref-text">NCT05288205 - Glecirasib + SHP2i</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT06380660" target="_blank">[NCT06380660 - PARP Inhibitor Trial]</a><span class="ref-text">NCT06380660 - PARP Inhibitor Trial</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT05269316" target="_blank">[NCT05269316 - ATR Inhibitor Trial]</a><span class="ref-text">NCT05269316 - ATR Inhibitor Trial</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://clinicaltrials.gov/study/NCT06819215" target="_blank">[NCT06819215 - VB15010 Trial]</a><span class="ref-text">NCT06819215 - VB15010 Trial</span></span></li>
<li><span class="ref-tooltip nccn-ref"><span class="cite cite-nccn">[NCCN]</span><span class="ref-text">NCCN: Colon Cancer v1.2025</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207981s008lbl.pdf" target="_blank">[FDA Label: LONSURF]</a><span class="ref-text">FDA Label: LONSURF</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s278lbl.pdf" target="_blank">[FDA Label: ERBITUX]</a><span class="ref-text">FDA Label: ERBITUX</span></span></li>
<li><span class="ref-tooltip"><a class="cite" href="https://civicdb.org/variants/78" target="_blank">[CIViC: KRAS G12C]</a><span class="ref-text">CIViC: KRAS G12C</span></span></li>
</ol>


      <div class="warning-box">
        <strong>⚠️ 安全警告</strong>
        <ul>

          <li>TAS-102 + 贝伐珠单抗: 需减量至 20mg/m² BID（若 CrCl &lt;30 或耐受差）</li>

          <li>肾脏: 肌酐 146 μmol/L，⚠️ 受损 (eGFR ~40-50)</li>

          <li>血液: PLT 偏低（既往），⚠️ 既往2级</li>

          <li>❌ 呋喹替尼 / 瑞戈非尼: 绝对禁忌，因既往严重 AKI 及当前肾功能不全</li>

          <li>⚠️ 雷替曲塞: 肾排泄药物，高风险，不建议再次使用。</li>

        </ul>
      </div>

    </div>

    <footer>
      <p><strong>免责声明:</strong> 本报告仅供临床参考。具体治疗决策应由主治医师根据患者实际情况和最新临床证据综合判断。</p>
      <p>虚拟分子肿瘤委员会会诊报告 | 生成日期: 2026-01-26 12:41:04</p>
    </footer>

  </div>
</body>
</html>
